a new drug soon to be authorized in the United States
Taken very early, it would slow down the disease, but experts consider its effects “modest” and accompanied by side effects. It’s called donanemab, and it’s in 2023 that it should get the green light from health authorities in the United States. Developed by the pharmaceutical group Eli Lilly, it is the publication on Monday of … Read more